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The B7 family-related protein V-set and Ig containing 4 (VSIG4), also known as
Z39Ig and Complement Immunoglobulin Receptor (CRIg), is the most recent of the
complement receptors to be identified, with substantially distinct properties from the
classical complement receptors. The receptor displays both phagocytosis–promoting
and anti-inflammatory properties. The receptor has been reported to be exclusively
expressed in macrophages. We now present evidence, that CRIg is also expressed
in human monocyte-derived dendritic cells (MDDC), including on the cell surface,
implicating its role in adaptive immunity. Three CRIg transcripts were detected and
by Western blotting analysis both the known Long (L) and Short (S) forms were
prominent but we also identified another form running between these two. Cytokines
regulated the expression of CRIg on dendritic cells, leading to its up- or down regulation.
Furthermore, the steroid dexamethasone markedly upregulated CRIg expression, and
in co-culture experiments, the dexamethasone conditioned dendritic cells caused
significant inhibition of the phytohemagglutinin-induced and alloantigen-induced T cell
proliferation responses. In the alloantigen-induced response the production of IFNγ,
TNF-α, IL-13, IL-4, and TGF-β1, were also significantly reduced in cultures with
dexamethasone-treated DCs. Under these conditions dexamethasone conditioned
DCs did not increase the percentage of regulatory T cells (Treg). Interestingly, this
suppression could be overcome by the addition of an anti-CRIg monoclonal antibody
to the cultures. Thus, CRIg expression may be a control point in dendritic cell function
through which drugs and inflammatory mediators may exert their tolerogenic- or
immunogenic-promoting effects on dendritic cells.
Keywords: dendritic cells, complement receptor immunoglobulin (CRIg), dexamethasone, cytokines, T cells,
immunosuppression
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INTRODUCTION
The Complement Receptor Immunoglobulin (CRIg), unlike
other complement receptors, is expressed selectively in
macrophages (1). The receptor plays a key role in the
phagocytosis and clearance of bacteria in a complement
dependent (1–3) and complement independent manner (4). But
in addition, it has been reported to inhibit T cell responses. Vogt
et al. (5) demonstrated that CRIg-Ig fusion protein inhibited
the anti-CD3 or anti-CD3/28 antibody(s) induced mouse and
human T cell proliferation and IL-2 production in vitro. When
this fusion protein was injected into mice, there was a reduction
in the numbers of antigen-induced CD8+ T cells and a reduction
in the IFN-γ producing population. In these mice the Th-
dependent IgG antibody response was reduced. CRIg expression
inmacrophages has been suggested to regulate the T cell response
(6, 7). We demonstrate that human DC express CRIg mRNA and
protein, including cell surface expression and that expression
could be modulated by cytokines. Furthermore, dexamethasone
was found to cause upregulation of CRIg expression on DC
which inhibited the mitogen- and alloantigen-induced T cell
response. This highlights an additional mechanism involved in
the regulation of the adaptive immune response.
METHODS
Cytokines and Cell Culture Reagents
Recombinant human cytokines used for DC treatments
were as follows: LT-α (TNF-β), GM-CSF, M-CSF, IL-1β,
IL-6, IL-4, TNF-α, IL-13, IFN-γ, IL-10 (ProSpec-Tany
Technogene, Rehovot, Israel) and TGF-β1 (R&D Systems,
Minneapolis, Minnesota, USA) were used in culture within
a final concentration range of 5–80 ng/ml. Dexamethasone
was used at a final concentration in culture at 30 ng/ml
(Sigma-Aldrich, St. Louis, MO). All cell culture experiments
utilized RPMI 1640 tissue culture medium, heat-inactivated
(56◦C/20min) fetal calf serum (FCS), penicillin/streptomycin
and L-glutamine (SAFC Biosciences, Lenexa, KS).
Antibodies
Anti-human protein antibodies used in this study were as follows:
mouse monoclonal anti-CRIg clone 3C9 (kindly provided
by Dr. van Lookeren Campagne, Genentech, San Francisco,
CA), phycoerythrin (PE)-conjugated and unconjugated anti-
CRIg clone 6H8 (Santa Cruz Biotechnology, Dallas, TX,
USA), fluorescein isothiocyanate (FITC)-conjugated anti-DC-
SIGN/CD209 clone 120507 (R&D Systems). Isotype controls
used were as follows: PE-conjugated and unconjugated mouse
IgG1 (eBioscience, San Diego, CA), and FITC-conjugated mouse
IgG2b (R&D Systems). The secondary antibody used for Western
blotting was horse-radish peroxidase (HRP)-conjugated rabbit
anti-mouse IgG (Dako, Glostrup, Denmark).
Preparation of Dendritic Cells
The study was approved by the CYWHS Human Ethics
Committee (approval number REC 2165/4/2011). Dendritic
cells were prepared from peripheral blood of healthy donors,
who had given informed consent, utilizing previously described
methods (8, 9). Blood was layered onto Ficoll R© Paque PLUS
(GE Healthcare, Uppsala, Sweden), d = 1.077, and centrifuged
at 400 × g for 30min. Firstly blood monocytes were prepared
as described previously (9). The peripheral blood mononuclear
cell (PBMC) layer was harvested and washed in RPMI-1640
medium with 2mM L-glutamine, 100 U/ml penicillin, 100µg/ml
streptomycin and 10% heat-inactivated FCS. Then, the PBMCs
were layered onto 46% iso-osmotic Percoll R© gradient (GE
Healthcare, Uppsala, Sweden) and centrifuged at 600 × g for
30min. After centrifugation the lymphocytes were pelleted, and
the upper monocyte-containing interphase layer was harvested
and washed, with preparations routinely being of >98% viability
and >90% purity by Giemsa. For all studies unless otherwise
stated, monocytes were seeded at 1 × 106 cells per 60 × 15mm
culture dish pre-treated with autologous plasma and left to
adhere at 37◦C for 1 h. Any contaminating non-adherent cells
were removed, and the adherent monocytes cultured with RPMI-
1640 medium with L-glutamine, penicillin, streptomycin, FCS,
50 ng/ml GM-CSF, and 20 ng/ml IL-4 at 37◦C in an atmosphere
of 95% air and 5% CO2 over 5 days for differentiation into DCs.
The DCs were harvested by gentle pipetting and washed prior to
use in experiments.
DC-T Cell Co-cultures
Autologous DC and T cell co-cultures were setup using DCs
as prepared above, with autologous T cells purified from the
remaining lymphocyte fraction following the centrifugation of
PBMC over 46% iso-osmotic Percoll R© gradient. The T-cells were
purified by subjecting the lymphocyte fraction through two cycles
of nylon wool (Polysciences Inc., Warrington, PA) columns using
an established protocol (10). The T-cell preparation was of >95%
purity and >99% viability as determined by FACS analysis and
trypan blue dye exclusion assay, respectively. The T cells were
cryopreserved in liquid nitrogen until use (11). The DCs were
added to 96-well round-bottom plate (Nunc) at 1× 104 cells/well
and treated with dexamethasone for 24 h and washed. The
cryopreserved T cells were thawed and added to the autologous
DC (2 × 105 T-cells/well). PHA was used as a stimulus in the
appropriate wells (0.5 µg/well) (Remel Inc., San Diego, CA),
with or without either anti-CRIg (clone 6H8) antibody or isotype
control. The cells were cultured at 37◦C in an atmosphere of 95%
air and 5% CO2 for 72 h. Cells were pulsed with 1 µCi methyl-
3H
Thymidine (3H-TdR) (PerkinElmer, Waltham, MA) 6 h prior to
harvest. 3H-TdR incorporation was measured as disintegrations
per minute (DPM) in a Wallac 1409 liquid scintillation beta
counter (Wallac, Turklo, Finland).
For allogeneic DC-T cell cultures, instead of autologous T
cells, allogeneic T cells were isolated from fresh or cryopreserved
PBMCs using the EasySepTM Human T Cell Isolation Kit (Stem
Cell Technologies, Vancouver, Canada), and added to allogeneic
DCs as the stimulus in a DC:T cell ratio of 1:10 as 2 × 105
total cells/well, with or without anti-CRIg antibody or isotype
control. DCs were untreated or dexamethasone treated DC at
2 × 104 cells/well in 96-well round-bottom plates. Cells were
cultured at 37◦C in an atmosphere of 95% air and 5% CO2 for
120 h and pulsed with 3H-TdR 6 h prior to harvest. At harvest,
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culture supernatants were harvested and stored at −80◦C for
later quantification of cytokines, followed by measurement of
the remaining cells for 3H-TdR incorporation. Cytokines in the
culture supernatants were quantitated with BDTM Cytometric
Bead Array kits for IFN-γ, TNF-α, IL-13, TGF-β1, IL-4, and IL-
10 (BD Biosciences) following adaptation of the manufacturer’s
protocols for assay in 96-well v-bottom plates, with acquisition
on a BD FACSCanto with an attached BDTM High Throughput
Sampler (HTS), and analysis with FCAP Array v3 software
(BD Biosciences).
In similar culture setups, we examined the T cells for the
presence of Treg cells in the alloreactive stimulation as above.
After 7 days of culture the cells were harvested and the levels of
CD4+CD25+ CD127loFoxp3+ cells measured by flow cytometry.
Anti-human CD4-FITC, CD25-PE-Cy7, CD127-Alexa Fluor
647, Foxp3-PE, and corresponding isotype controls were from
BD Biosciences. Cell surfaces were stained with appropriate
antibodies for 20min at room temperature (RT), washed once
with PBS supplemented with 0.1% FCS, and incubation for
60min at RT in Fixation/Permeabilization buffer (eBioscience).
Following washing with Permeabilization buffer (eBioscience)
and blocking with mouse IgG for 10min at RT, intracellular
staining of Foxp3 was performed in Permeabilization buffer with
30min incubation at RT with the appropriate antibody or isotype
control. Acquisitionwas performed on a BDFACSCanto and data
analyzed using FlowJo v10.1 (FlowJo, LLC, Ashland, Oregon).
The gating strategy to identify Foxp3+ Tregs is described in
Supplementary Figure 3.
Measurement of CRIg by RT-PCR and
qPCR
For determination of total CRIg mRNA levels and isoform
transcript detection, RNA was isolated using a RNeasy R©
Plus kit (Qiagen, Venlo, Limburg, Netherlands) according
to the manufacturer’s instructions, and treated with DNase
I (DNA-free Kit, Ambion, Life Technologies, Mulgrave, Vic,
Australia) to remove any genomic DNA contamination. The
quantity of RNA was assessed on a NanoDropTM (Thermo
Fisher Scientific, MA, USA), and converted to cDNA using
the iScriptTM cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA).
Reverse transcriptase (RT)-PCR for CRIg isoform transcripts
was conducted as previously described (12), using primers for
isoform 1 (F1: TTTGTGGTCAAAGACTCCTCAAAGC; and
R1: TGGCATGTGCCCTGGCT), isoform 2 (F2: TGTCCAGA
AACACTCCTCAAAGCT; and R1), isoform 3 (F2; and R2:
GAGAGACTTTCTTACCTGGCTGCTT), isoform 4 (F1 and
R2), and isoform 5 (F1; and R3: GACACTTTGGGCTGGC
TGCT). GAPDH primer sequences were used as previously
described (12) (F: GAGTCAACGGATTTGGTCGT; R: GACA
AGCTTCCCGTTCTCAGCCT). Separate reactions were set up
for each isoform, containing 100 nM of each primer (pairing
as described above), 1 µl of cDNA, and AmpliTaq Gold R© 360
Master Mix (Applied Biosystems) in a 25 µl final volume. PCR
reactions were performed with an initial denaturation at 95◦C
for 7min, followed by 35 cycles of 95◦C for 30 s, 60◦C for 30 s,
and 72◦C for 60 s, and a final extension at 72◦C for 7min, using
a SimpliAmpTM Thermal Cycler (Applied Biosystems). The RT-
PCR products were visualized following electrophoresis on a 2%
GelRed-stained agarose gel (Biotium) along with a 1 kb Plus DNA
Ladder (Invitrogen).
qPCR for total CRIg mRNA expression was conducted as
previously described (12) using the primer pair detecting all
five known isoforms of CRIg (F: ACACTTATGGCCGTCCCAT;
R: TGTACCAGCCACTTCACCAA) with the GAPDH primer
pair described above for expression data normalization. Each
reaction had a final volume of 20 µl containing 100 nM of each
primer, 1 µl of cDNA, and iQ SYBR Green Supermix (Bio-Rad
Laboratories). Triplicate reactions were assayed in an iQ5 Real
Time Detection System with iQ5 Optical System v2.1 software
(Bio-Rad Laboratories), with thermal cycling performed with an
initial denaturation at 95◦C for 5min, followed by 40 cycles of
95◦C for 30 s, 60◦C for 30 s, and 72◦C for 30 s.
Measurement of CRIg Cell-Surface
Expression
The expression of CRIg on the cell surface of DCs was measured
by flow cytometry. At the conclusion of treatment, 1.5 × 105
harvested DCs had Fc receptors on their surface blocked with ice-
cold PBS supplemented with 0.5% (w/v) BSA, 10mg/ml Intragam
P, and 5% (v/v) human AB serum for 30min. PE-conjugated
anti-CRIg (clone 6H8) or isotype control antibodies, along with
FITC-conjugated anti-CD209 antibodies were incubated with the
DCs in a final staining volume of 50 µl for 30min. The cells were
washed in PBSwith 0.5% (w/v) BSA, and following centrifugation
(600 × g for 5min), the cells were then fixed in PBS containing
1% (v/v) formaldehyde. A minimum of 20,000 events were
acquired from the stained DC samples on a BD FACSCanto
(BD Biosciences, CA, USA), with data analysis performed with
FlowJo 10.1 (FlowJo, LLC, Ashland, Oregon). Doublets were
excluded by gating with SSC-A vs. SSC-H. Trypan blue was
used to determine cell viability (>95%) following harvest and
prior to flow cytometric staining. Using 7-aminoactinomycin D
(7-AAD), we were able to demonstrate specific DC viability in a
set of replication experiments (Supplementary Figure 1) where
similar results of enhanced CRIg expression by dexamethasone
treatment was found.
Western Blotting for CRIg Isoforms
Western blot for CRIg expression in DCs was performed using
methods previously described (13). DCs harvested from each
culture were lysed in 100 µl of 20mMHEPES, pH 7.4, with 0.5%
(v/v) Nonidet P-40, 100mM NaCl, 1mM EDTA, 2mM Na3VO4,
2mM dithiothreitol, 1mM phenylmethylsulfonyl fluoride and
10µg/ml leupeptin, aprotonin, pepstatin A, and benzamidine, for
2 h at 4◦C with constant mixing. These samples were centrifuged
at 12,000 × g for 5min to obtain lysates (supernatants), and the
protein content quantitated by Lowry assay, prior to the addition
of Laemmli buffer supplemented with 3% β-mercaptoethanol.
The lysates were boiled at 100◦C for 5min and 60 µg of protein
loaded and electrophoresed on 12% SDS polyacrylamide gels,
followed by transfer of protein onto nitrocellulose membrane
(Pierce Biotechnology, Thermo Fisher Scientific, Rockford, IL).
The membrane was stained with 0.1% Ponceau S (in 5% acetic
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acid) to ascertain protein loading equality. The amounts of
the CRIg L, S and I isoforms were detected using monoclonal
mouse anti-human CRIg clone 3C9 and HRP-conjugated rabbit
anti-mouse IgG. The immune complexes on the membranes
were visualized by enhanced chemiluminescence on a ChemiDoc
XRS+ Imaging System and quantitated using Image LabTM
software version 3.0 (Bio-Rad Laboratories, Hercules, CA).
Statistical Analysis
Statistical significance was calculated using GraphPad Prism 7.0
(GraphPad Software, Inc., La Jolla, CA, USA), with testing as
follows: two-way ANOVA with post-hoc Bonferroni’s Multiple
Comparison testing for relative CRIg protein isoforms; Student t-
testing for relative CRIg surface expression and dexamethasone-
modulated CRIg mRNA expression; One-way ANOVA with
post-hoc Dunnett’s Multiple Comparison testing for cytokine
dose-dependent CRIg mRNA expression; and One-way ANOVA
with post-hoc Bonferroni’s Multiple Comparison testing for 3H-
TdR incorporation between DC-T cell co-culture treatments.
Statistical significance was defined as P < 0.05.
RESULTS
Expression of CRIg on Human DC
Human monocyte derived dendritic cells (MDDC) were
generated in culture by treating monocytes with IL-4 and
GM-CSF. The MDDC expressed CRIg mRNA by RT-PCR
(Figure 1A) and CRIg protein on their surface by flow cytometry
analysis (Figure 1B). Examination of transcripts showed that
at least three isoforms of CRIg were present (Figure 1A).
Furthermore, by Western blot analysis we identified the
expression of the prominent long (L) and short (S) isoforms,
as previously described in human macrophages (1) and an
additional intermediate form migrating between the L and S
isoforms (Figure 1C).
Dexamethasone Increases CRIg
Expression in DC Leading to
Immunosuppression
Previously, we have demonstrated that the anti-inflammatory
steroid dexamethasone is a strong enhancer of CRIg expression
in human macrophages (12, 14, 15). In addition, it has
been reported that DC generated under the influence of
dexamethasone have a tolerogenic functional phenotype (16). It
was therefore of interest to determine whether dexamethasone
alters the expression of CRIg on DC. The MDDC were
treated with varying concentrations of dexamethasone for 24 h,
washed and CRIg expression measured. Dexamethasone caused
an increase (3-fold) in CRIg mRNA levels (Figure 1D). This
was reflected in an increase in CRIg protein measured by
Western blotting (Figure 1C). Examination of the Western
blots also revealed that dexamethasone caused an increase
in the levels of all 3 isoforms of CRIg on DC (Figure 1C).
The changes induced by dexamethasone were also evident in
expression of CRIg on the surface of DC (Figure 1E), which has
implications for the function of DC as antigen presenting cells
and adaptive immunity.
To assess the functional consequences of increasing CRIg
expression, we examined whether DC which had been treated
with dexamethasone, expressing increased amounts of cell
surface CRIg, were immunosuppressive in cell co-culture studies.
Mononuclear leukocytes (MNL) from single individuals were
separated into T cells and monocytes. The T cells were
cryopreserved and the monocytes were treated with GM-CSF
and IL-4 to allow development into DC. Then, the T cells
were thawed and reconstituted with DC which had been pre-
treated with either diluent or dexamethasone. The cells were
stimulated with phytohemagglutinin (PHA) and proliferation
was measured by a radiometric assay. The data showed that T
cells cultured in the presence of dexamethasone conditioned DC
were significantly depressed in proliferation (Figure 2A). Further
studies examined the importance of surface expressed CRIg
in the immunosuppression by adding anti-CRIg monoclonal
antibody to the cultures (clone 6H8, Santa Cruz Biotechnology,
Dallas, TX). The results showed that the suppression by
dexamethasone conditioned DC could be completely prevented
by the antibody (Figure 2A). The normalized data has been
presented in Supplementary Figure 3.
In the second set of experiments, the effects of dexamethasone
were assessed in an allogeneic T cell stimulation culture model.
Monocyte derived DC were treated with dexamethasone, washed
and added to allogeneic T cells. After 5 days of culture the culture
fluids removed and the cells were replenished with fresh medium
containing 3HTdR and harvested after 6 h of further incubation.
The amount of radioactivity incorporated was determined
and proliferation quantitated. The dexamethasone treated DCs
caused a significant decrease in the allogeneic proliferative
response (Figure 2B). When anti-CRIg monoclonal antibody
was added to the cultures the effect was essentially abolished,
suggesting that CRIg played a role in the immunosuppression.
When we examined the cytokines IFNγ, TNF-α and IL-4, IL-13,
IL-10, and TGF-β1 in the supernatants from these cultures, we
observed that production of all these cytokines was significantly
reduced in the presence of dexamethasone treated DCs except
for IL-10 (Figures 2C–H), and that the addition of anti-CRIg
monoclonal antibody prevented this suppression in cytokine
production (Figures 2C–G). Examination of the lymphocyte
population for Treg cells demonstrated that based on the
expression of CD127, CD25, and FoxP3 expression there was no
increase but if anything a decrease in this subset (Figure 2I). The
normalized data has been presented in Supplementary Figure 3.
Th1 and Th2 Cytokines Alter the
Expression of CRIg
In all of the following studies, we used CRIg+ DC that had
been derived from monocytes cultured in the presence of GM-
CSF and IL-4. No dexamethasone treatment was conducted. Our
study examined the effects of four cytokines, IFN-γ and LT-
α representing Th1 cell and IL-4 and IL-13 representing Th2
cell products on DC CRIg expression. When CRIg+ DC were
treated with LT-α for 24 h, the cells showed a concentration
dependent decrease in CRIgmRNA over a concentration range of
5–40 ng/ml (Figure 3A). This effect was supported by the finding
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FIGURE 1 | CRIg expression in MDDC and effects of dexamethasone. (A) CRIg isoform transcripts detected in DC. Agarose gel electrophoresis (2%) was used to
visualize transcript variant amplicons generated from the cDNA of HMDC. Lanes are labeled 1, 2, 3, 4, and 5 representing each CRIg isoform with (–) to the right of
each isoform lane indicating the respective no template controls. GAPDH was a positive control. Gels are representative of three experiments. (B) Gating strategy for
CRIg expression on DC by flow cytometry. CD209+ cells were gated before assessing anti-CRIg antibody (6H8-PE) staining; representative histogram shown. (C)
CRIg isoform expression by Western blot using anti-CRIg monoclonal antibody (clone 3C9). A representative blot of total protein stained with Ponceau S shows
consistency of protein loading. Band intensity for each isoform (L, I, and S) over protein load was determined by densitometry. Data are expressed as fold-change over
control DC (n = 3). (D) Relative CRIg mRNA expression as detected by qPCR, normalized to GAPDH, expressed as fold-change over control DCs (n = 3). (E) Relative
CRIg cell-surface expression by flow cytometry. Data are expressed as fold-change in CRIg-PE (6H8) mean fluorescence intensity minus isotype control (IgG1) of
treated over control DCs (n = 7); representative histogram shown. Data are presented as means ± SEM of experiments conducted with cells from different individuals.
Significance levels are indicated by asterisks: *P < 0.05, ****P < 0.0001.
that LT-α caused a significant decrease in total CRIg protein
measured by Western blotting (Figure 3B), with a concomitant
decrease of the L and S as well as the intermediate isoforms.
A corresponding effect on cell surface expression was observed
(Figure 3C). Treatment with 5–40 ng/ml of IFN-γ showed a
similar decrease in CRIg mRNA, total protein and cell surface
expression as seen with LT-α (Figures 3D–F).
The Th2 cytokines, IL-4, and IL-13 caused an even more
profound decrease in CRIg expression in the DC (Figure 4).
The cytokines caused a decrease in CRIg mRNA expression over
a concentration range of 5–40 ng/ml. A similar decrease was
observed when total CRIg protein was measured by Western
blot (Figures 4B,E). Expression of all three CRIg isoforms was
decreased by treatment with either IL-4 or IL-13. However, this
decrease was not reflected in a reduced expression of cell surface
CRIg (Figures 4C,F).
The Regulatory and Immunosuppressive
Cytokines Increase CRIg Expression
The cytokine TGF-β1 regulates inflammation and IL-10 has
immunosuppressive activity (17–19). Their action could in
part be through the regulation of CRIg on DC. We found
that MDDC treated with IL-10 for 24 h showed a significant
increase in CRIgmRNA expression in a concentration dependent
manner (Figure 5A). Examination by Western blot showed a
corresponding increase in CRIg protein expression (Figure 5B).
However, this increase was not as evident in cell surface CRIg
expression (Figure 5C). TGF-β1 also increased CRIg expression
of mRNA, total CRIg protein and cell-surface expression on DC
(Figures 5D–F). Examination of cell lysates subjected toWestern
blots showed that both TGF-β1 and IL-10 caused an increase in
the levels of the L and S isoforms as well as the intermediate form
on DC (Figures 5B,E).
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FIGURE 2 | Effects of dexamethasone conditioned DCs and anti-CRIg monoclonal antibody on PHA- and allogeneic-induced T cell proliferation, cytokine production
and generation of iTreg. (A) 3H-TdR incorporation (DPM) in autologous DC-T cell co-culture in the presence/absence of dexamethasone, anti-CRIg 6H8 or isotype
control antibodies, and PHA. Data are presented as means ± SEM of 6 experiments conducted with cells from different individuals. (B) 3H-TdR incorporation (DPM) in
allogeneic DC-T cell co-culture in the presence/absence of dexamethasone treated DCs, anti-CRIg 6H8 antibody or isotype control antibodies. Data are presented as
mean ± SEM of 5 experiments. (C–H) Effects on cytokine production in allogeneic DC-T cell cultures. Data are presented as mean ± SEM of 4–5 experiments. (I)
Effects on generation of iTreg in allogeneic DC-T cell cultures. Data are presented as mean ± SEM of 4 experiments. Note that normalized data for the above cytokine
production and Treg generation is presented in Supplementary Figure 3. Significance levels are indicated by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.
Effects of Pyrogenic Cytokines on the
Expression of CRIg in DC
The cytokines TNF-α, IL-1β, and IL-6 are pyrogenic cytokines
(20, 21) which have direct effects on monocytic cells, including
the modulation of macrophage and DC differentiation (22–25)
or macrophage function and cell death (26, 27). Since these
are produced during the innate phase of the inflammatory
response, they may influence the adaptive immune response
through their effects on DC. It was therefore of interest
to examine this group of cytokines on CRIg expression in
DC. Cells treated for 24 h with either TNF-α, IL-1β, or IL-6
showed a significant decrease in CRIg mRNA expression, in
a concentration dependent manner (Figure 6). This effect was
reflected in the total CRIg protein expression decreased by the
cytokines. However, there was no corresponding decrease in
cell surface expression, apart from TNF-α (Figure 6). It was
also evident that both TNF-α and IL-1β caused a decrease in
all three isoforms of CRIg, shown by Western blot analyses
but the S form was not significantly decreased by the IL-6
treatment (Figures 6B,E,H).
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FIGURE 3 | LT-α and IFN-γ decrease CRIg expression in DC. (A,D) DC were treated with varying concentrations of cytokines and the levels of CRIg mRNA
determined after 24 h of culture. (B,E) In other experiments, CRIg isoform proteins were assessed by Western blot after cells were treated with 40 ng/ml of each of the
cytokines. (C,F) The effects on cell surface expression of CRIg was examined after a similar treatment. Data are presented as means ± SEM of three experiments,
each conducted with cells from different individuals. The blot image (E) was spliced to exclude intervening lanes that represent other treatments and the complete
un-spliced blot can be found in Supplementary Figure 2. Significance levels are indicated by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001.
Effect of Colony Stimulating Factors,
M-CSF, and GM-CSF
Both M-CSF and GM-CSF have been reported to alter DC
differentiation and/or function (22, 28). Examination of the
effects of M-CSF and GM-CSF on the expression of CRIg in
DC showed that cells treated with M-CSF display a marked
increase in CRIg mRNA expression (Figure 7A). The increase
paralleled the increase seen in total CRIg protein assayed by
Western blot. The cytokine caused several-fold increase in the
levels of CRIg protein expression (Figure 7B). Similar increases
in CRIg expression of mRNA and total protein (Figures 7D,E)
occurred in the presence of GM-CSF. However, we found that
neither of these cytokines caused any changes in expression of
cell surface CRIg (Figures 7C,F). As with other cytokines, all
three isoforms of CRIg were concomitantly increased by the
CSFs (Figures 7B,E).
DISCUSSION
The data provide evidence that CRIg is expressed by human
monocyte derived dendritic cells (MDDC). Expression is
observed at the mRNA, protein and cell surface level. The level
of expression may dictate whether the cell promotes T cell
responsiveness or unresponsiveness. Thus, increasing the surface
expression of CRIg by treating with dexamethasone rendered
the DC not capable of supporting the T cell response to PHA
or alloantigen stimulation. Evidence that the dexamethasone-
conditioned DC work through CRIg is provided by the finding
that addition of an anti-CRIg monoclonal antibody to the
cultures prevents the immunosuppression in both culture
models. It has already been suggested that CRIg participates
in adaptive immunity (5, 6, 29, 30). While Xu et al. (29)
did not find CRIg expression in human MDDC, when these
cells were transfected with the CRIg gene (representing the
L form), the protein was expressed. The induced expression
of CRIg in the transfected DC led to an immunosuppressed
response or tolerance (29). This supports our data that CRIg
expression regulates immune responsiveness. The inability to
show expression in the non-transfected cells may be due to the
fact that Xu et al. (29) treated the cells with TNF-α toward
the end of their maturation phase. Our results show that
TNF-α causes the down regulation of CRIg expression. While
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FIGURE 4 | IL-4 and IL-13 down regulate CRIg expression in DC. (A,D) DC were treated with a dose range of the cytokines for 24 h and then examined for CRIg
mRNA expression. (B,E) The levels of total CRIg isoform proteins measured by Western blot in DC treated with 20 ng/ml of cytokines. (C,F) Similarly treated DC were
examined for surface expression of CRIg by flow cytometry. Data are presented as means ± SEM of at 3–4 experiments, each conducted with cells from a different
individual. Significance levels are indicated by asterisks: **P < 0.01, ***P < 0.001, ****P < 0.0001, whilst n.s. indicates non-significance.
further studies need to be undertaken with DCs from different
tissues, transcriptomic data indicate that CRIg is likely to be
expressed in tissue DCs (Supplementary Figure 4). It is evident
that expression ranges from medium to high in different DC
types but expression can be as high as in macrophages. Of
interest, although in limited studies, Tanaka et al. (31) described
surface expression CRIg+ dendritic-like cells in the synovial
tissue from rheumatoid arthritis, osteoarthritis and psoriatic
arthritis patients.
Examination of the culture fluids in our DC-T allogeneic
cell cultures for cytokine production supported the
immunosuppressive effects of dexamethasone treated DCs,
acting via CRIg expression. The dexamethasone-conditioned
DCs-T cell cultures produced significantly less Th1 cytokines,
IFN-γ, and TNF-α, as well as reduced Th2 cytokines, IL-4,
and IL-13. In addition, the production of regulatory cytokine
TGF-β1 was also reduced. With respect to all of these cytokines,
the addition of anti-CRIg monoclonal antibody prevents
the decrease in cytokine production. This indicates that the
major effect precipitating the immunosuppression is the
increased CRIg expression on the DCs. In mouse T cell
cultures, Yuan et al. (7) showed that CRIg-Ig fusion protein
suppressed the phosphorylation of signaling molecules, such
as ZAP-70, ERK1/2, and Akt, thus acting early in the T
cell activation response. Such inhibition was likely to cause
the reported CRIg-Ig-mediated suppression of mTORC1
activation, thereby promoting inducible (i)Treg generation
(32). Furthermore, the immunosuppressive effects of CRIg are
unlikely to result from changes in proportions of Treg cells,
since these were not increased but in fact decreased in these
cultures, consistent with decreased production of the regulatory
cytokine TGF-β1. In contrast, in mice CRIg-Ig fusion protein
promoted the differentiation of Treg cells and the stabilization
of Foxp3, although this was less evident when CRIg expressing
macrophages were used (7). Whether these differences are due to
macrophages vs. DCs or mouse vs. human leukocytes, as well as
other factors, remain to be identified.
Expression on the cell surface indicates that CRIg will
have the ability to mediate the tolerogenic properties of DC.
Inevitably the level of CRIg expression on these cells may be a
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FIGURE 5 | IL-10 and TGF-β1 increase CRIg expression in DC. (A,D) DC were treated with varying concentrations of the cytokines for 24 h and then examined for
CRIg mRNA expression. DC were treated with either 40 ng/ml of IL-10 or 25 ng/ml of TGF-β1 and CRIg isoform protein expression in DC lysates (B,E) or CRIg
expression on the cell surface (C,F) were measured. Data are presented as means ± SEM of three experiments, each conducted with cells from different individuals.
The blot image in (E) was spliced to exclude intervening lanes that represent other treatments and the complete un-spliced blot can be found in
Supplementary Figure 2. Significance levels are indicated by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, whilst n.s. indicates non-significance.
determining factor as to the potency of a resultant immunogenic
or tolerogenic response the T cells may express, as the DC
transform from providing an immunostimulatory signal to a
tolerogenic signal following expression of CRIg (29). Thus,
the composition of cytokine milieu at tissue sites is likely to
be important in determining the role played by DC in the
adaptive immune response, to which CRIg contributes. Our data
demonstrate that cytokines significantly modulate the expression
of CRIg in MDDC. CRIg expression on DC was increased by
TGF-β1, IL-10, M-CSF, and GM-CSF. In comparison, LT-α, IFN-
γ, IL-4, IL-13, TNF-α, IL-1β, and IL-6 decreased expression.
In this manner, the cytokines could participate in tolerogenic
vs. immunogenic responses, respectively through their ability
to alter expression of CRIg on DC. However, it is not clear
as to why DC treated with some cytokines did not show
a corresponding alteration in expression at the cell surface.
This may be an assay time related effect. But the ability of a
cytokine to increase the intracellular CRIg levels may operate
collaboratively with another cytokine to increase release to the
cell surface, an area for future investigation. It is therefore
tempting to speculate that inflammatory mediators may regulate
expression at the transcriptional, translation and release to
the cell surface. The regulatory effects of cytokines on CRIg
expression has also been demonstrated for macrophages (12, 33).
Supplementary Table 1 depicts the effects of cytokines on CRIg
expression in MDM and MDDC. While most of the cytokines
had similar effects on both cell types, LT-α, GM-CSF and the
regulatory cytokines, IL-10 and TGF-β1, had the opposite effects
on the two cell types.
The finding that IL-10 and TGF-β1 cause an increase in CRIg
expression on DC is of interest and importance in adaptive
immunity and immune responsiveness. Tolerogenic DC can
be generated by immunosuppressive cytokines including IL-
10, TGF-β1 (34–37), and immunomodulatory drugs, such as
dexamethasone (38). Since tolerogenic DC are being considered
as a therapeutic strategy in transplantation (39) and autoimmune
inflammatory diseases (40, 41), these findings are likely to be
helpful in developing tolerogenic DC for this purpose. IL-10
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FIGURE 6 | Effect of TNF-α, IL-1β, and IL-10 on CRIg expression in DC. (A,D,G) DC were treated with varying concentrations of the cytokines for 24 h and then
examined for CRIg mRNA expression. For examination of CRIg isoform protein expression (B,E,H) and cell surface expression (C,F,I), the cells were treated with
40 ng/ml of cytokine. Data are presented as means ± SEM of three experiments, each conducted with cells from different individuals. Significance levels are indicated
by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, whilst n.s. indicates non-significance.
caused a substantial increase in CRIg mRNA and corresponding
CRIg protein in human DCs. Dexamethasone treated DCs
generates tolerogenic DCs that have reduced alloantigenic
capacity, higher IL-10 secretion and inhibit Th2 differentiation
of naïve CD4+ T cells in latex-allergic patients (42).
Our findings of CRIg being expressed by DC have important
implications in autoimmunity, chronic inflammation and cancer
(43). CRIg expression has been associated with decreased T
cell and B cell responses (5, 44). The importance of CRIg
in protecting against autoimmune inflammation has been
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FIGURE 7 | M-CSF and GM-CSF increase CRIg in DC. (A,D) DC were treated with varying concentrations of the CSF and the CRIg mRNA expression determined.
Changes in CRIg isoform proteins (B,E) and cell surface (C,F) CRIg expression on DC treated with 40 ng/ml of each CSF are shown. Data are presented as means ±
SEM of three experiments, each conducted with cells from different individuals. Significance levels are indicated by asterisks: *P < 0.05, **P < 0.01, ****P < 0.0001,
whilst n.s. indicates non-significance.
demonstrated in experimental models of inflammatory arthritis
(45), renal tubulointestitial injury (46), lupus nephritis (47),
immune-mediated liver injury (48), type 1 diabetes (7, 30),
and inflammatory bowel disease (49). In addition, the levels
of CRIg expression in macrophages has been associated with
disease severity in rheumatoid arthritis (31, 50) and patients
with cirrhosis and ascites (51). In cancer, the level of CRIg
expression by tumor associated macrophages has been shown
to be a prognostic marker for tumors metastasizing, with high
expression being prognostic for poor outcome (52–54). This
also raises the potential for CRIg being a check point in the
development of metastatic cancer and hence a drug target.
Our results demonstrate that three transcripts of CRIg are
expressed in human MDDC. By Western blot analysis, we were
able to identify the L and S isoforms along with an additional
form not previously described and designated as the intermediate
or I form. This most likely corresponds to the third transcript
detected by PCR. However, because of lack of appropriate
monoclonal antibodies specific for the different CRIg isoforms,
we were not able to relate these to the changes seen in the
Western blots. Nevertheless, it is evident that the I isoform is less
prominent than the L and S isoforms. While the function of the
I form remains unknown, it is tempting to speculate that since
some of the extracellular domain is the same as the short form,
its interaction with ligands should be the same. But because the I
form has absence of intracellular phosphorylation sites as a result
of alternative splicing, it is questionable that this form would be
able to signal.
The ability of cytokines and dexamethasone to regulate
the expression of CRIg was evident at the mRNA level
and this correlated with protein expression, suggesting that
inflammatory mediators and the immunosuppressive drug act
at the pre-transcriptional level. It has been postulated by
us that dexamethasone acts via the glucocorticoid receptor
to downregulate CRIg expression as well as acting via the
inhibition of PKCα activation and increasing CRIg expression
in this manner (15). While the mechanisms of CRIg+ antigen
presenting cell-induced immunosuppression remain to be
elucidated, it has recently been demonstrated that engaging this
receptor in macrophages reprograms the mitochondrial pyruvate
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metabolism and inhibits their activation (55). Here we have not
only shown the expression of CRIg on DC, but that increased
expression can lead to suppression of T lymphocyte proliferation.
This provides important support for its role in protection
against autoimmune inflammatory diseases and poor prognosis
in metastasizing cancer (43). Furthermore, the findings expand
our knowledge on CRIg and the regulation of the adaptive
immune response, from that of its elegant role in clearance of
pathogens and regulation of the alternative complement pathway
activation (56, 57).
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